Wed Nov 06 17:04:20 UTC 2024: ## Masimo Stock Soars to 52-Week High on Strong Earnings

**Sioux Falls, SD** – Masimo Corporation (NASDAQ: MASI) shares surged to a new 52-week high on Wednesday, propelled by a robust earnings report that exceeded analysts’ expectations. The stock climbed as high as $173.90 before settling at $164.09, reflecting a significant increase from its previous close of $151.56.

The medical equipment provider reported earnings per share of $0.98 for the quarter, surpassing analyst estimates of $0.84 by $0.14. Revenue also outpaced predictions, reaching $504.60 million compared to the expected $502.87 million. This represents a 5.4% year-over-year increase in revenue.

Masimo’s impressive financial performance has garnered positive attention from Wall Street. Piper Sandler upgraded their price target on Masimo to $180.00, while Raymond James boosted the company’s rating to “outperform” with a target price of $170.00. BTIG Research also increased their target price to $170.00 and maintained a “buy” rating.

These positive assessments reflect a growing confidence in Masimo’s future prospects, fueled by its innovative patient monitoring technologies and automation solutions. The company’s focus on noninvasive monitoring solutions, particularly in the area of pulse oximetry, has proven to be a key driver of its success.

Despite the recent surge, Masimo’s stock remains a subject of debate among analysts. While several analysts have issued “buy” ratings, others maintain a “hold” rating, suggesting a more cautious approach. MarketBeat currently assigns the company a “Moderate Buy” rating with an average price target of $151.00.

Hedge funds have also shown interest in Masimo, with several institutions increasing their stakes in the company over recent quarters. This suggests a belief in the company’s long-term growth potential and the strength of its market position.

With its focus on innovation and its strong financial performance, Masimo appears well-positioned to continue its growth trajectory in the rapidly evolving medical technology industry.

Read More